Mesothelioma Treatment Options

Overview of Mesothelioma Treatment

Modern mesothelioma treatment follows a multimodal approach, combining two or more treatment types — surgery, chemotherapy, immunotherapy, and radiation — for optimal outcomes. Treatment selection depends primarily on disease stage, cell type (epithelioid vs. sarcomatoid vs. biphasic), tumor resectability, and patient performance status. The FDA-approved first-line regimen combines pemetrexed, cisplatin, and nivolumab plus ipilimumab immunotherapy, which improved median overall survival to 18.1 months in the CheckMate 743 trial.

The specific treatment plan depends on several critical factors:

• Stage of the cancer — earlier stages (I and II) offer more options, including curative-intent surgery
• Cell type (histology) — epithelioid responds best to treatment; sarcomatoid and biphasic are more resistant to chemo but may respond well to immunotherapy
• Tumor location — pleural (lung lining), peritoneal (abdominal lining), pericardial (heart lining), or tunica vaginalis
• Overall patient health — age, lung function, cardiac health, and performance status determine surgical candidacy

The Multimodal Standard of Care

The NCCN guidelines recommend multimodal therapy as the standard of care. Our mesothelioma treatments comparison breaks down each approach side by side. Common approaches include surgery + chemotherapy + radiation (trimodal), surgery + neoadjuvant or adjuvant chemotherapy, immunotherapy alone or with chemotherapy for unresectable disease, and chemotherapy + radiation for non-surgical patients.

Chemotherapy for Mesothelioma

Chemotherapy uses anti-cancer drugs to kill mesothelioma cells throughout the body. It serves as primary treatment for non-surgical candidates, as neoadjuvant therapy (before surgery) to shrink tumors, or as adjuvant therapy (after surgery) to target remaining cancer cells.

First-Line Chemotherapy: Pemetrexed + Cisplatin

The standard first-line regimen is pemetrexed (Alimta) combined with cisplatin, established by the landmark EMPHACIS trial published in the New England Journal of Medicine in 2003:

• Median survival of 12.1 months versus 9.3 months with cisplatin alone
• Response rate of approximately 41% — tumor shrinkage in nearly half of patients
• Improved time to progression of 5.7 months versus 3.9 months

For patients who cannot tolerate cisplatin, carboplatin is used as a substitute with comparable efficacy and a more favorable side effect profile, particularly for older patients or those with kidney concerns.

Neoadjuvant vs. Adjuvant Chemotherapy

Neoadjuvant chemotherapy is administered before surgery (typically 3–4 cycles of pemetrexed + cisplatin) to shrink the tumor and improve surgical outcomes. Adjuvant chemotherapy is given after surgery (typically 4–6 cycles) to target any microscopic cancer cells that may remain. The neoadjuvant approach also allows oncologists to assess tumor responsiveness to chemotherapy before committing to surgery.

Second-Line Options

When first-line chemotherapy fails, second-line options include gemcitabine (alone or in combination), vinorelbine, retreatment with pemetrexed for patients who had an initial response, and immunotherapy with nivolumab + ipilimumab, which is increasingly used as second-line therapy.

Common Side Effects

Chemotherapy side effects commonly include fatigue, nausea, decreased appetite, low blood counts (neutropenia, anemia, thrombocytopenia), kidney effects (with cisplatin), and neuropathy. Folic acid and vitamin B12 supplementation is required with pemetrexed to reduce toxicity. Most side effects are manageable with supportive medications and dose adjustments.

Radiation Therapy for Mesothelioma

Radiation therapy uses high-energy beams to kill cancer cells and shrink tumors. In mesothelioma, radiation is used as an adjuvant treatment after surgery, as palliative therapy for symptom relief, or as part of a trimodal approach. Radiation alone is not curative, but it plays an important supporting role in multimodal plans.

Intensity-Modulated Radiation Therapy (IMRT)

IMRT is the most commonly used radiation technique for mesothelioma. It uses computer-controlled linear accelerators to deliver precise radiation doses that conform to the three-dimensional shape of the tumor while minimizing exposure to surrounding healthy tissues — particularly the lungs, heart, and liver. IMRT is especially valuable after P/D surgery, where the lung remains in place and must be protected from radiation damage.

Adjuvant Radiation After Surgery

Following EPP (where the lung has been removed), radiation can be delivered to the entire hemithorax at higher doses because there is no remaining lung tissue to protect. After P/D (where the lung is preserved), radiation delivery is more technically challenging and requires IMRT or other precision techniques to avoid damaging the preserved lung.

SMART Technique

The Surgery for Mesothelioma After Radiation Therapy (SMART) approach reverses the traditional sequence by delivering high-dose, short-course radiation before surgery. Developed at Princess Margaret Cancer Centre in Toronto, SMART involves 5 consecutive days of high-dose hemithoracic radiation followed by EPP within one week. Early results have shown improved local control and promising survival outcomes in selected patients.

Palliative Radiation

For patients who are not candidates for curative-intent treatment, radiation therapy can provide significant symptom relief — reducing chest wall pain, relieving shortness of breath caused by tumor compression, preventing tumor growth at biopsy or surgical port sites (prophylactic tract irradiation), and managing symptoms from metastatic disease.

Emerging & Experimental Treatments

Several experimental approaches beyond standard surgery, chemotherapy, immunotherapy, and radiation are showing promise. While not yet standard of care, these represent the future direction of mesothelioma therapy and are available through clinical trials at select centers.

Tumor Treating Fields (TTFields / Optune)

TTFields uses low-intensity, alternating electric fields delivered through transducer arrays worn on the chest to disrupt cancer cell division. The STELLAR trial showed a median overall survival of 18.2 months when combined with chemotherapy — comparable to immunotherapy results. TTFields received FDA Humanitarian Device Exemption approval for mesothelioma (NovoTTF-100L / Optune Lua).

Gene Therapy

Gene therapy delivers therapeutic genes directly into tumor cells to make them more vulnerable to the immune system or to chemotherapy. Adenovirus-mediated gene therapy using the interferon-alpha gene has been studied in mesothelioma clinical trials, with some patients showing tumor regression and improved survival.

Photodynamic Therapy (PDT)

PDT involves administering a light-sensitive drug that accumulates in cancer cells, then activating the drug with a specific wavelength of light during surgery to destroy residual tumor cells. PDT has been studied as an intraoperative adjunct to P/D surgery at the University of Pennsylvania, with early results showing improved local control.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy engineers a patient's own immune cells to recognize and attack specific proteins on mesothelioma cells. Researchers have developed CAR-T cells targeting mesothelin — a protein highly expressed on mesothelioma cells — with clinical trials underway at Memorial Sloan Kettering and other institutions. Early-phase results have shown that CAR-T cells can infiltrate mesothelioma tumors and produce anti-tumor responses.